Min Cui, Ph.D., is the Founder and Managing Director of Decheng Capital. See sector focus and contact routes.
Min Cui, Ph.D., is the Founder and Managing Director of Decheng Capital, a venture firm he established in 2011 that focuses on building global biotechnology and medical technology companies. His investment thesis targets early-stage life science firms with innovative technologies and growth-stage healthcare companies with market traction, primarily operating in the biotech and medtech sectors across the United States and China. While specific check sizes and lead/follow behavior are not publicly detailed, Decheng Capital manages over $2 billion in capital and provides both funding and strategic assistance to its partners. Cui holds board seats at numerous notable portfolio companies, including Nuvation Bio (NASDAQ: NUVB), Mammoth Biosciences, Mirvie, and Shape Therapeutics. He also serves on the boards of Alpine Immune Sciences, EpimAb Biotherapeutics, and Cue Health, reflecting a deep commitment to the life sciences ecosystem. A distinctive point of view is his emphasis on partnerships with entrepreneurs to build companies globally, leveraging his academic background with a Ph.D. in Cancer Biology from Stanford University. Cui additionally se
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Menlo Park when building a target list.
Investors like Min Cui · Full investor directory · Investor access · Company funding database